Madrigal Pharmaceuticals opened at $431.55, in line with its previous close of $431.70. In the last trading session, the stock traded between $425.00 and $437.80. It showed a sideways intraday trend.
An investment of $100 made 5 years ago in Madrigal Pharmaceuticals is now worth
$ 551.30
giving a profit of
$ 451.30 (451.30%)
Note: Past profits do not guarantee future returns.
Rating from 10 Analysts
Today's Change
$-3.06 (-0.71%)
Day High
$437.80
Day Low
$425.00
Day Open
$431.55
Prev Close
$431.70
Volume
1,01,422
1W Return
-5.44%
1M Return
-15.74%
3M Return
-21.52%
6M Return
-17.34%
1Y Return
1.67%
Market Cap ($ Mn)
9,903
PE Ratio
-
PB Ratio
23.57
PEG Ratio
-
ROE
-42.53%
ROCE
-34.15%
EPS (TTM)
$-2.51
1 Week
-5.44%
1 Month
-15.74%
3 Months
-21.52%
6 Months
-17.34%
9 Months
-13.35%
Madrigal Pharmaceuticals grants 9,642 RSUs to new employees
Granted 9,642 restricted stock units to 26 new non-executive employees. Awards issued under the 2025 Inducement Plan per Nasdaq Rule 5635(c)(4). RSUs vest in four equal annual installments contingent on continued employment. Grants occurred on October 1 and October 14, 2026.
14 days agoMadrigal grants equity awards to 27 new hires under Nasdaq rule
Madrigal Pharmaceuticals granted equity awards to 27 new non-executive employees in September 2026. Awards include 2,754 stock options at $538.71 per share and 16,149 restricted stock units. Grants were approved under Nasdaq Listing Rule 5635(c)(4) as inducements for employment. Options vest quarterly after the first year, while RSUs vest annually over four years.
1mo agoMadrigal grants 4,676 RSUs to 13 new hires as inducement
Madrigal granted 4,676 RSUs to 13 new non-executive employees. Awards serve as inducement under Nasdaq Listing Rule 5635(c)(4). Units vest in four equal annual installments over four years. Rezdiffra remains first FDA-approved treatment for MASH with fibrosis.
2mo agoOne-third of treated MASH patients show suboptimal results despite therapy uptake
One-third of treated MASH patients show suboptimal results or need treatment changes. Prescription therapy required for 71% to 74% of diagnosed MASH patients. Nine-in-ten patients on Rezdiffra or Wegovy are new initiations, not switchers. Physicians prefer augmenting regimens over switching due to limited alternatives. Dual therapy candidates include nearly half of patients not currently on combinations.
2mo agoMadrigal Pharmaceuticals Q2 Results: EPS beats estimates, sales up 71%
Madrigal Pharmaceuticals delivered better-than-expected Q2 results with an EPS of $(1.99), beating the $(2.50) estimate. Sales jumped 71.17% YoY to $364.252 million, surpassing the $353.178 million forecast. The beat reflects strong operational execution despite a slight widening of YoY losses.
3mo agoMadrigal grants inducement awards to ten new employees
Madrigal Pharmaceuticals granted equity awards to ten new non-executive employees on July 15, 2026 under its 2025 Inducement Plan. The awards include options to purchase 4,770 shares at $550.25 per share, 7,433 time-based RSUs, and 1,908 performance-based RSUs. Vesting is tied to employment tenure and performance metrics, with performance-based units potentially vesting in Q1 2029.
3mo ago| Stock | LTP | Change % | Market Cap | PE |
|---|---|---|---|---|
| $540.00 | +1.95% | $1,36,868.94M | 31.55 | |
| $61.07 | +2.12% | $1,31,639.87M | 14.39 | |
| $222.76 | +4.01% | $88,933.81M | - | |
| $818.77 | +0.68% | $82,808.76M | 19.64 | |
| $897.85 | +0.68% | $56,462.20M | 38.99 | |
| $371.56 | -0.48% | $40,792.43M | 65.60 | |
| $190.27 | +0.82% | $40,781.71M | - | |
| $56.49 | -1.40% | $35,253.15M | 26.24 | |
| $65.93 | +1.71% | $29,357.11M | 32.37 | |
| $37.52 | +1.10% | $27,101.56M | - | |
| $111.59 | +15.07% | $24,369.25M | - | |
| $116.80 | -0.06% | $23,675.13M | 15.85 |
An investment of $100 made 5 years ago in Madrigal Pharmaceuticals is now worth
$ 551.30
giving a profit of
$ 451.30 (451.30%)
Note: Past profits do not guarantee future returns.
